Generated by AI
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing protein kinase inhibitor therapies for cardiopulmonary and neurodegenerative diseases. Its current portfolio is centered on pulmonary arterial hypertension, where it is advancing an oral prodrug of imatinib mesylate designed to address disease pathways linked to abnormal kinase signaling. The company also maintains a neuroscience-oriented program targeting Parkinson’s disease and related disorders through Abelson tyrosine kinase inhibition. Inhibikase Therapeutics works across areas of rare disease, cardiopulmonary medicine, and neurology, with a business model built around small-molecule drug development and clinical research. Headquartered in Wilmington, Delaware, Inhibikase Therapeutics plays a specialized role in the biopharmaceutical market by pursuing therapies for conditions with limited treatment options and significant unmet medical need.
Website1000 N. West Street
Wilmington, DE, 19801
United States
The latest articles about IKT.
Tipranks Press Release.
Summary of Feb 25's posts. Generated by AI.
Summary of Feb 23's posts. Generated by AI.
Summary of Feb 23's posts. Generated by AI.
Investors talking about IKT also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.